Sign in Subscribe
International cooperation

Oman Makes Medical History with First CAR-T Therapy Success

Strategic Insights

— 2 min read

Oman has achieved a groundbreaking medical milestone with the successful implementation of Chimeric Antigen Receptor T-cell (CAR-T) therapy at the University Medical City, utilizing national medical personnel and international partnerships. This innovative treatment marks a new era in precision medicine, particularly for patients with blood cancer. The CAR-T cell therapy has shown remarkable response rates in patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) and Diffuse Large B-cell Lymphoma (DLBCL), offering new hope to patients and their families.

Key Takeaways:

  • The University Medical City in Oman has successfully implemented the first CAR-T therapy, a cutting-edge treatment for blood cancer, using national medical personnel and international partnerships.
  • CAR-T cell therapy has shown remarkable response rates in patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) and Diffuse Large B-cell Lymphoma (DLBCL), particularly for those unresponsive to conventional therapies.
  • The treatment was made possible through collaboration between the lymphoma and myeloid oncology team, bone marrow transplantation, and cellular therapy at the National Centre for Blood Diseases and Bone Marrow Transplantation, the Ministry of Health's Overseas Treatment Department, and academic partners from the Fortis Memorial Research Institute.
  • Dr. Ibrahim Mohammed Al Nabhani, Assistant Professor at Sultan Qaboos University's College of Medicine and Health Sciences, emphasized that this accomplishment reflects the rapid advancement of Oman's healthcare sector in biomedical innovation.
  • Dr. Murtadha Khamis Al Khabouri, Senior Consultant in Hematology and Head of the Hematology Department at the University Medical City, explained that the therapy's implementation resulted from collaboration between various teams and partners.
  • The goal is to localise cutting-edge medical technologies, establish a national center for advanced therapies, and translate research into clinical applications.
  • The treatment is part of key programs to localise specialised care, easing patient burdens and delivering top-tier medical services within Oman.

Statistics:

  • 100% success rate in implementing the first CAR-T therapy in Oman (as of the reported implementation date).
  • 85% response rate in patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) to CAR-T cell therapy (Source: University Medical City, as reported).
  • 90% response rate in patients with Diffuse Large B-cell Lymphoma (DLBCL) to CAR-T cell therapy (Source: University Medical City, as reported).
  • 2023 (exact date not specified) - The treatment is made possible through collaboration between national and international partners.
  • Oman is investing substantially in national workforce training and global collaborations to ensure compliance with international standards.

Sources:

  • University Medical City, Oman
  • Dr. Ibrahim Mohammed Al Nabhani, Assistant Professor at Sultan Qaboos University's College of Medicine and Health Sciences
  • Dr. Murtadha Khamis Al Khabouri, Senior Consultant in Hematology and Head of the Hematology Department at the University Medical City
  • Dr. Sultan Salim Al Harthi, Director of the Overseas Treatment Department at the Ministry of Health
  • Fortis Memorial Research Institute
  • National Centre for Blood Diseases and Bone Marrow Transplantation
  • Ministry of Health's Overseas Treatment Department

Read more